Stocks · News reference
This Honeywell Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday
Top Wall Street analysts upgraded Grupo Cibest, Lufax, Honeywell, and Gossamer Bio. JBS also received an upgrade. See what analysts think.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Logistic Properties Of The Americas Agrees To Sell Income-Producing Facilities Located Within Parque Logístico Calle 80 In Bogotá, Colombia, To Grupo Cibest’s Bancolombia For ~$152M In All-Cash Transaction
Third disposition of 2026 lifts completed and announced transactions to more than US$300 million; retained, fully serviced land preserves development upside and positions LPA for its next phase in ColombiaLogistic
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
With bond yields declining and Social Security concerns mounting, retirees are turning to dividend-paying stocks as an alternative income source. The article recommends investing in high-quality dividend stocks with consistent dividend growth histories to combat inflation and supplement retirement income, while cautioning against high-fee mutual funds and ETFs.
Beat the Market the Zacks Way: FIGS, Microsoft, Amphenol in Focus
Zacks Investment Research showcases the performance of its various stock rating systems and portfolios. The Zacks Rank #1 portfolio outperformed the S&P 500 by 2.3 percentage points year-to-date, while individual stocks like FIGS and CRL surged following rank upgrades. The Focus List, ECAP, ECDP, and Top 10 portfolios also demonstrated strong returns, with the Top 10 portfolio delivering a cumulative return of +2,881.3% since 2012 compared to the S&P 500's +648.5%.
Chardan Capital Initiates Coverage On Gossamer Bio with Buy Rating, Announces Price Target of $160
Chardan Capital analyst Andreas Argyrides initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Buy rating and announces Price Target of $160.
8-K filing — Gossamer Bio, Inc. (GOSS)
Filed: 2026-09-28 AccNo: 0001728117-26-000106 Size: 138 KB Item 8.01: Other Events